Fibrocell Science Appoints Greg Weaver Chief Financial Officer, Senior Vice President, Treasurer and Corporate Secretary Seasoned biotech CFO with a wide range of public and VC-backed company experience Rodman & Renshaw Global Investment Conference 2013 Business Wire EXTON, Pa. -- August 26, 2013 Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications, announced today the appointment of Greg Weaver as Chief Financial Officer, Senior Vice President, Treasurer and Corporate Secretary of the Company. Weaver replaces Declan Daly, who will leave the company to reside full time in Ireland. Weaver and Daly will work side by side through November 2013 to assure a smooth financial leadership transition. Weaver brings more than thirty years of strategic and financial management experience to Fibrocell, where he will be responsible for the company's day-to-day financial operations at the corporate offices in Exton, Pa. He joins Fibrocell from oncology drug development company Celsion Corp. where he served as chief financial officer after serving six years on Celsion's board of directors. Prior to Celsion, Weaver served as CFO for six other biotechnology companies, including Poniard Pharmaceuticals, Talyst, Inc., Sirna Therapeutics, Nastech Pharmaceutical Co., Ilex Oncology and Prism Technologies and consulted for countless others. Over the course of his career, he has managed corporate and situation-specific financing strategies, dramatically increased multiple market cap valuations and overseen multiple product and service revenue channels, and manufacturing supply relationships. “I am confident that Greg’s wealth of experience working with growth companies will provide Fibrocell with a strong foundation for continued expansion," said David Pernock, Chairman and Chief Executive Officer of Fibrocell Science. “It excites me that Fibrocell has a presence in aesthetics and that they are steadily expanding into medical markets to address unmet needs,” Weaver said. “I am eager to join the Fibrocell team and am confident that my experience growing biotechnology companies will help catapult the Company toward its future milestones.” Weaver will join Mr. Pernock at the Rodman & Renshaw 15^th Annual Global Investor Conference for the Company’s presentation on Tuesday, September 10 at 11:15 a.m. About Fibrocell Science, Inc. Fibrocell Science, Inc. (NYSE MKT:FCSC) is an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com. Contact: Investor Relations The Ruth Group Zack Kubow/Melanie Sollid-Penton 646-536-7020/7023 firstname.lastname@example.org email@example.com or Media Marina Maher Communications, LLC Heather Adamson, 212-485-6806 firstname.lastname@example.org
Fibrocell Science Appoints Greg Weaver Chief Financial Officer, Senior Vice President, Treasurer and Corporate Secretary
Press spacebar to pause and continue. Press esc to stop.